Tizona com­pletes spin­out of can­cer pro­gram as part of Gilead buy­out; Dyne files for $100M IPO

Tizona has com­plet­ed the spin­out of a new com­pa­ny that will fo­cus on de­vel­op­ing its now-for­mer lead pro­gram in­volv­ing an an­ti-CD39 an­ti­body.

The new com­pa­ny …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER